Associate Professor Kate Burbury is consultant haematologist; Director of Digital and Healthcare Innovations and Deputy Chief Medical Officer at the Peter McCallum Cancer Centre.
Kate is the lead for Digital health, healthcare innovations, healthcare research and implementation, and the strategy for building our regional partnerships around Victoria and interstate. She is also the Haematology Disease Group lead for myeloproliferative disorders (MPD)/chronic myeloid leukaemia (CML) and lead clinician for haemostasis, thrombosis and peri-operative optimisation, including pre-habilitation, for all patients with cancer at PeterMac.
Kate is a member of professional societies, scientific committees, council member for Haematology Society for Australia and New Zealand, and actively involved in the development of expert guidelines and governance structures for both the institution and external working parties, including European Leukaemia Network: flow cytometry in myelodysplastic syndromes (MDS).
Kate has an active translational research and clinical trial portfolio, with a particular interest in MPD, CML, FC in MDS and the haemostatic/endothelial dysfunction associated with malignancy. She has published numerous peer-reviewed manuscripts, regular presents at national and international scientific meetings, a member of editorial boards and reviewer for numerous journals.
Kate is committed to clinical and translational research, and the provision of the best care to patients through their treatment journey.
2015: Victorian Public Health Minister’s Award for Excellence in Cancer Care
2014: Peter Mac Awards Team Excellence
2008: ASTH medal runner-up
2008: ASTH Travel award
2007: ASTH medal runner-up